Go to content | Go to menu | Go to search
Close
You are about to leave zentiva.com
The link you are about to open is not maintained by Zentiva and may potentially be unsafe.
July 11, 2025 / 2025
Zentiva is proud to announce a significant step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi). By setting near term and long-term net-zero Green House Gas (GHG) reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns our decarbonisation roadmap with the European Union’s goal of becoming the first climate-neutral continent by 2050.
July 9, 2025 / 2025
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.
June 30, 2025 / 2025
As the EU adapts to global geopolitical tensions and renews its focus on simplifying legislation, Medicines for Europe convened policymakers, industry leaders, and partners for its annual meeting in Brussels.
June 16, 2025 / 2025
Propol2 EMF, Ruscoven, Serenil, Fisiodepur and Finocarbo will become part of Zentiva’s portfolio
May 30, 2025 / 2025
At Zentiva, we believe that each of us can contribute to taking care of our planet and doing what we can to protect it so that future generations can enjoy life as much as we do.
May 21, 2025 / 2025
Zentiva supported Euractiv’s Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled “The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All.”
July 11, 2025 / 2025
Zentiva is proud to announce a significant step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi). By setting near term and long-term net-zero Green House Gas (GHG) reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns our decarbonisation roadmap with the European Union’s goal of becoming the first climate-neutral continent by 2050.
July 9, 2025 / 2025
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.
June 30, 2025 / 2025
As the EU adapts to global geopolitical tensions and renews its focus on simplifying legislation, Medicines for Europe convened policymakers, industry leaders, and partners for its annual meeting in Brussels.
June 16, 2025 / 2025
Propol2 EMF, Ruscoven, Serenil, Fisiodepur and Finocarbo will become part of Zentiva’s portfolio
May 30, 2025 / 2025
At Zentiva, we believe that each of us can contribute to taking care of our planet and doing what we can to protect it so that future generations can enjoy life as much as we do.
May 21, 2025 / 2025
Zentiva supported Euractiv’s Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled “The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All.”
December 17, 2024 / 2024
Key takeaways included the emerging risk of medicine shortages. This not only contradicts the solidarity principle of the European Union but also burdens the industry with added costs and administrative demands.
December 9, 2024 / 2024
November 18, 2024 / 2024
November 12, 2024 / 2024
We are proud to announce that Zentiva has successfully achieved the SAP Customer Center of Expertise (CCoE) certification.
November 8, 2024 / 2024
In this episode, you will learn about data from beehive colonies turned into smart insights, helping us determine the ecological impact humans have in a certain area. In a nutshell, this AI-driven project uses bees as our smart environmental sensors to achieve sustainability goals.
December 18, 2023 / 2023
The General Assembly focused on critical issues such as EU pharmaceutical legislation that delivers on accessibility, affordability and availability of the medicines, removing any barriers and delays, and environmental impact.
December 14, 2023 / 2023
As a leader in the pan-European pharmaceutical platform, Zentiva actively shares its experience and explores advancements in energy efficiency management through its participation in dedicated events.
November 14, 2023 / 2023
We act today for a sustainable tomorrow continuously reducing our environmental impact and we are on our path to becoming carbon neutral in 2030.
October 24, 2023 / 2023
CPHI is one of the largest and most sought-after event in the pharmaceutical industry. We are excited to meet and discuss with our current, as well as future potential partners.
December 22, 2021 / 2021
Zentiva opens vaccination site for employees and their families at its Prague plant
November 3, 2021 / 2021
October 12, 2021 / 2021
September 24, 2021 / 2021
September 16, 2021 / 2021
October 25, 2019 / 2019
Zentiva Acquires Central and Eastern European Business of Alvogen
September 11, 2019 / 2019
Zentiva enhances its global manufacturing footprint by signing an agreement to acquire manufacturing site in Ankleshwar, India
May 31, 2019 / 2019
Zentiva announces completion of Solacium Pharma acquisition
April 1, 2019 / 2019
Zentiva Group a.s. is announcing the acquisition of Creo Pharmaceuticals Ltd. in the UK, a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
March 13, 2019 / 2019
Zentiva Group a.s. and Siyiara Enterprises have signed a Shared Purchase Agreement for the acquisition of Romanian based pharmaceutical company Solacium, together with its subsidiary Be Well Pharma.
November 23, 2018 / 2018
Zentiva and PHOENIX joined forces this week for an inaugural Annual Partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe.
October 1, 2018 / 2018
oday marks generics manufacturer Zentiva’s first day as an independent organization, following completion of the company’s previously announced divestment from Sanofi.
June 28, 2018 / 2018
Sanofi and Advent International (“Advent”) have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion (enterprise value).
 |
|
|
 |
Pantone |
2727 |
 |
Pantone |
339 |
Explore our other LinkedIn accounts:
Head of Communications
Telephone: (+420) 267 241 111
Email: zentiva@zentiva.com
